Novo Nordisk ranks 4th among the world's top 20 science employers

Novo NordiskNovo Nordisk was just ranked number four on the Science 2012 Top Employer list - up from ninth place last year. The company's 'social responsibility', 'respect for employees' and ability to inspire 'loyalty among its employees' were cited as key drivers of this impressive global ranking.

"We're proud to have jumped to the top five in this widely-recognised ranking of the world's best science employers. Our excellent researchers around the world are the main source of this company's strong innovation. The fact that they feel respected and take pride in working for a company that operates in a sustainable way is great to see. In the battle to recruit the best researchers, there's nothing more powerful than peer-to-peer communication," says Mads Krogsgaard Thomsen, chief science officer and executive vice president at Novo Nordisk.

R&D professionals at Novo Nordisk comprise world-class experts in the engineering, expression, formulation and delivery of therapeutic proteins, as well as in the development of compounds into safe, effective and convenient treatment options for people living with chronic conditions like diabetes, haemophilia and rheumatoid arthritis. More than 4,000 employees work in Novo Nordisk R&D in Denmark, US, China and India.

"This positive evaluation of Novo Nordisk resonates well with my own personal experience as a diabetes researcher in the company for the past 21 years. Our collaborative work in multidisciplinary teams both within and outside of the company, and our openness to explore new ideas inspire me. It gives me the confidence that I'm part of a highly-qualified team working every day to find better treatment solutions for people with diabetes," says Erica Nishimura, scientific director of Diabetes Biology at Novo Nordisk.

In the Science 2012 survey, 4,276 employees working in the biotechnology, biopharmaceutical, pharmaceutical and related industries were asked to rank the 20 best employers based on 23 characteristics, including research-driven environment and financial strength.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Most Popular Now

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

FDA accepts regulatory submission for Lynparza in …

AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Three of the most deadly cancers get critical fund…

Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the de...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]